• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: February 2022

Pharma & Human Health

Researchers discover unique lysin capable of killing deadly multidrug-resistant bacteria

February 20, 2022 Microbiome Times

Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology(SMART), MIT’s research enterprise in Singapore, alongside collaborators at Nanyang Technological University, have identified a novel phage lysin – […]

Editor's Choice

A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology

February 18, 2022 Kristina Campbell

Benjamin Rubin was a post-doc in the lab of Jennifer Doudna—a Nobel-prize-winning scientist who pioneered CRISPR-Cas9—when a colleague got him thinking about a microbial ecology problem. He started to wonder: could it be possible to […]

Finance

Recipharm acquires Arranta Bio

February 18, 2022 Microbiome Times

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the acquisition of Arranta Bio, a prominent advanced therapy CDMO. Under the stewardship of Mark Bamforth and backed by Ampersand Capital Partners, the […]

Biotech Showcase

Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132

February 17, 2022 Jean de Gunzburg

  This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]

Biofortis

EasyBioM® – Data Visualisation in a few clicks

February 16, 2022 Erwann Scaon

We are faced with the generation of very large volumes of complex NGS data, which presents a huge challenge for its analysis, and with the question how we can derive a simple scientific interpretation and […]

Pharma & Human Health

Fecal implants drive behavioral and cognitive changes in Alzheimer’s model

February 12, 2022 Microbiome Times

New research in mice for the first time draws a definitive causal connection between changes in the gut microbiome to behavioral and cognitive changes in an animal model of Alzheimer’s disease. The study, published today […]

Pharma & Human Health

New “vertical map” of airborne microorganisms indicates how global warming will impact global ecosystems

February 11, 2022 Microbiome Times

In a landmark study of airborne microorganisms from ground level up to 3,500 metres, scientists from the Singapore Centre for Environmental Life Sciences Engineering (SCELSE) at Nanyang Technological University, Singapore (NTU Singapore) have found that […]

Finance

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

February 10, 2022 Microbiome Times

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a securities purchase agreement to […]

Finance

MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies

February 9, 2022 Microbiome Times

MaaT Pharma, a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer and Skyepharma, a Contract Development and Manufacturing Organization […]

Pharma & Human Health

BioGaia’s probiotic reduces inflammation in patients with diverticulitis

February 9, 2022 Microbiome Times

A randomized, double-blind, placebo-controlled study with BioGaia’s probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 was shown to reduce inflammation significantly more than placebo in patients with acute uncomplicated diverticulitis. Moreover, as hospitalization time was shorter in the […]

Editor's Choice

ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

February 7, 2022 Craig Thomson and Jennifer Bailey

Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University.  […]

Posts navigation

1 2 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • New standards in sensitivity and accuracy for microbiome research
    September 20, 2023
  • Integrating Microbiome and Dietary Data: Microbiome Data Congress 2023
    August 22, 2023
  • Distinguishing Strains in Microbiome Samples: Considerations and Challenges
    July 19, 2023
  • Proven Complementary Effect of Probiotic Yeast and Bacteria
    June 21, 2023
  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
sign up

Sign up to the Microbiome Times newsletter